US20220089647A1 - Cyclic peptide, cell scaffold material, cell separating material, and medium - Google Patents

Cyclic peptide, cell scaffold material, cell separating material, and medium Download PDF

Info

Publication number
US20220089647A1
US20220089647A1 US17/643,533 US202117643533A US2022089647A1 US 20220089647 A1 US20220089647 A1 US 20220089647A1 US 202117643533 A US202117643533 A US 202117643533A US 2022089647 A1 US2022089647 A1 US 2022089647A1
Authority
US
United States
Prior art keywords
amino acid
acid residue
cyclic peptide
hcy
dab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/643,533
Other languages
English (en)
Inventor
Koichi Minami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Assigned to FUJIFILM CORPORATION reassignment FUJIFILM CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MINAMI, KOICHI
Publication of US20220089647A1 publication Critical patent/US20220089647A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/02—Separating microorganisms from their culture media
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/14—Scaffolds; Matrices
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins

Definitions

  • the present disclosure relates to a cyclic peptide, a cell scaffold material, a cell separating material, and a medium.
  • Integrin is a cell adhesion molecule and is a heterodimeric protein consisting of two subunits, an ⁇ chain and a ⁇ chain. Integrin plays an important role not only in cell adhesion but also in cel extension, cell migration, cell proliferation, tissue formation, cancer metastasis, tissue repair, blood coagulation, and the like.
  • JP2005-507376A discloses a cyclic peptide that is cyclized by a disulfide bond and that binds to integrin.
  • Other cyclic peptides having an affinity to integrin are also known.
  • JP1994-509551A JP-H6-509551A discloses a cyclic peptide obtained by cyclizing Tyr-Arg-Gly-Asp, as a platelet aggregation inhibitor having high specificity to GP II b III a .
  • Bioconjugate Chem., 1995, 6, p. 269-277 describes a technique for subjecting a peptide to cyclization and/or binding to a carrier protein or glass coverslip using (bromoacetyl) diaminopropionic acid.
  • An object to be achieved by an aspect according to the present disclosure is to provide a cyclic peptide excellent in the binding property to integrin and excellent in the molecule stability, for example, in the alkali resistance, and a cell scaffold material, a cell separating material, and a medium, which contain the cyclic peptide.
  • the technique for achieving the above object includes the following aspects.
  • a cyclic peptide comprising:
  • a cyclic segment comprising an RGD sequence and having 8 to 14 amino acid residues
  • a thioether bond being formed between an amino acid residue X a located on a most N-terminal side of the cyclic segment and an amino acid residue X b located on a most C-terminal side of the cyclic segment,
  • an ⁇ carbon of the other amino acid residue of the amino acid residue X a and the amino acid residue X b is separated from a sulfur atom of the cysteine residue by five or more atoms.
  • cyclic peptide according to ⁇ 1> further comprising at least one of a first segment between the cyclic segment and an N-terminal of the cyclic peptide or a second segment between the cyclic segment and a C-terminal of the cyclic peptide, in which the at least one of the first segment or the second segment comprises an amino acid residue having an immobilizing functional group in a side chain.
  • ⁇ 3> The cyclic peptide according to ⁇ 2>, in which the immobilizing functional group is an amino group or a thiol group.
  • cyclic peptide according to ⁇ 2> in which the amino acid residue having the immobilizing functional group in a side chain is selected from the group consisting of an L-lysine residue, a D-lysine residue, an L-cysteine residue, a D-cysteine residue, an L-homocysteine residue, and a D-homocysteine residue.
  • ⁇ 5> The cyclic peptide according to any one of ⁇ 2> to ⁇ 4>, in which, in a case of being present, each of the first segment and the second segment has a length of 1 to 20 amino acid residues.
  • ⁇ 6> The cyclic peptide according to any one of ⁇ 1> to ⁇ 5>, in which one of the amino acid residue X a and the amino acid residue X b is an amino acid residue of the following (p) or (q),
  • * is a bonding site to an adjacent amino acid residue; ** is a bonding site to a sulfur atom of an amino acid residue which is a counterpart in the thioether bond;
  • x1 is an integer of 0 or more; xl pieces of carbon atoms and a carbon atom at a ⁇ -position may be substituted with one or more substituents selected from the group consisting of —NH 2 , —SH, —COOH, a C 1 -C 10 alkyl group, and a C 6 -C 14 aryl group;
  • **-L is **—(CH 2 ) y1 —C( ⁇ O)— or **—(CH 2 ) y1 —C( ⁇ O)—NH—, where y1 represents an integer of 0 or more and 10 or less;
  • the other of the amino acid residue X a and the amino acid residue X b is an residue of the following (t) or (u), and
  • * is a bonding site to an adjacent amino acid residue;
  • *** is a bonding site to a carbon atom of an amino acid residue which is a counterpart in the thioether bond;
  • x2 is an integer of 0 or more; and x2 pieces of carbon atoms and a carbon atom at a ⁇ -position may be substituted with one or more substituents selected from the group consisting of —NH 2 , —SH, —COOH, a C 1 -C 10 alkyl group, and a C 6 -C 14 aryl group;
  • the other of the amino acid residue X a and the amino acid residue X b is not an L-cysteine residue or a D-cysteine residue.
  • ⁇ 9> The cyclic peptide according to any one of ⁇ 6> to ⁇ 8>, in which the amino acid residue of the (p) or the (q) is a residue selected from the following (a) to (h):
  • amino acid residue of the (t) or the (u) is selected from the group consisting of an L-homocysteine residue, a D-homocysteine residue, an L-penicillamine residue, a D-penicillamine residue, an L-cysteine residue, and a D-cysteine residue;
  • cyclic peptide according to any one of ⁇ 1> to ⁇ 9>, in which the cyclic peptide comprises a plurality of the cyclic segments, and the amino acid sequences of the respective cyclic segments may be the same or different from each other.
  • cyclic peptide according to ⁇ 10> in which the plurality of the cyclic segments are connected to each other by a connecting moiety having a length of 1 to 20 amino acid residues.
  • ⁇ 12> The cyclic peptide according to any one of ⁇ 1> to ⁇ 11>, in which a total number of amino acid residues is 8 to 50.
  • X a represents the amino acid residue X a
  • X b represents the amino acid residue X b ;
  • X represents any amino acid residue, where in a case where a plurality of X's are present, the plurality of X's may be the same or different from each other;
  • R N represents an N-terminal group
  • R C represents a C-terminal group
  • X 6 and X 7 each independently represent an amino acid residue having an immobilizing functional group in a side chain, where in a case where a plurality of X 6 's or X 7 's are present, the plurality of X 6 's or X 7 's may be the same or different from each other;
  • n and n are integers and simultaneously satisfy 0 ⁇ m ⁇ 9, 0 ⁇ n ⁇ 9, and 3 ⁇ m+n ⁇ 9;
  • p0 and q0 are integers and respectively satisfy 0 ⁇ p0 ⁇ 15 and 0 ⁇ q0 ⁇ 15;
  • t0 and u0 are integers and respectively satisfy 0 ⁇ t0 ⁇ 5 and 0 ⁇ u0 ⁇ 5;
  • v0 and w0 are integers and respectively satisfy 0 ⁇ v0 ⁇ 5 and 0 ⁇ w0 ⁇ 5;
  • p0, q0, t0, u0, v0, and w0 further satisfy 0 ⁇ p0+q0+t0+u0+v0+w0 ⁇ 39.
  • X a -X m -R-G-D-X n -X b in Formula II is X a -X t v5 -X 1 -X 2 -R-G-D-X 3 -X 4 -X 5 v6 -X t v7 -X b
  • X t represents any amino acid residue, and in a case a plurality of X t 's are present, the plurality of X t 's may be the same or different from each other;
  • X 1 represents I, V, D, E, Y, L, T, or homotyrosine;
  • X 2 represents P, T, or S;
  • X 3 represents N, S, T, V, A or homoserine;
  • X 4 represents F, Y, or P;
  • X 5 represents R, D, E, A, T, S, or G;
  • v5 and v7 each independently represent an
  • an amino acid residue represented by X 1 is I, V, or T,
  • (v) v6 represents 1, and an amino acid residue represented by X 5 is A.
  • ⁇ 16> The cyclic peptide according to any one of ⁇ 1> to ⁇ 15>, in which an amino acid sequence of a region which resides between the amino acid residue X a and the amino acid residue X b has 70% or more of a sequence identity with respect to an amino acid sequence of IPRGDNFR (SEQ ID NO: 1) or has 70% or more of a sequence identity with respect to any one of amino acid sequences of IPRGDSFA (SEQ ID NO: 170), VPRGDTFA (SEQ ID NO: 171), or TPRGDTFA (SEQ ID NO: 172).
  • a cell scaffold material comprising a base material and the cyclic peptide according to any one of ⁇ 1> to ⁇ 16>.
  • a cell separating material comprising a holding material and the cyclic peptide according to any one of ⁇ 1> to ⁇ 16>.
  • a medium comprising a culture component and the cyclic peptide according to any one of ⁇ 1> to ⁇ 16>.
  • a cyclic peptide excellent in the binding property to integrin and excellent in the molecule stability for example, in the alkali resistance, and a cell scaffold material, a cell separating material, and a medium, which contain the cyclic peptide.
  • a range of numerical values shown using “to” in the disclosure means a range including numerical values before and after “to” as a minimum value and a maximum value.
  • an upper limit value and a lower limit value disclosed in a certain range of numerical values may be replaced with an upper limit value and a lower limit value disclosed in another range of numerical values disclosed in stepwise.
  • an upper limit value and a lower limit value disclosed in a certain range of numerical values may be replaced with values shown in examples.
  • the amount of each of components means the total amount of the plurality of substances.
  • process includes not only an independent process but also a process that cannot be clearly distinguished from other processes, as long as the intended purpose of the process is achieved.
  • the cyclic peptide according to the present disclosure contains a cyclic segment containing an RGD sequence and having 8 to 14 amino acid residues, in which a thioether bond is formed between an amino acid residue X a located on a most N-terminal side of the cyclic segment and an amino acid residue X b located on a most C-terminal side of the cyclic segment.
  • an ⁇ carbon of the other amino acid residue of the amino acid residue X a and the amino acid residue X b is separated from a sulfur atom of the cysteine residue by five or more atoms.
  • An integrin-binding cyclic peptide has an ability to bind to integrin which is a cell adhesion molecule. Since the integrin-binding cyclic peptide has an ability to bind to integrin on the cell surface, it can be used as a scaffolding material for cell culture, as a cell separating material for cell separation, and as a medium, and thus is a useful molecule. However, while a cyclic peptide may have a high binding property and a high specificity as compared with a linear peptide, the molecule stability of the cyclic peptide tends to be low as compared with the linear peptide.
  • a cyclic peptide tends to have low alkali resistance; low acid resistance; and low resistance to actinic rays such as an X ray and a ⁇ ray.
  • the integrin-binding cyclic peptide is also degraded during long-term use or repeated use due to low molecule stability thereof, and thus the desired effect could not be obtained for a long period of time.
  • a cyclic peptide does not always have a higher binding property than a linear peptide, and the binding property to integrin changes depending on the amino acid sequence of the cyclic peptide. As a result, it has not been easy to obtain an integrin-binding cyclic peptide having both an excellent molecule stability and an excellent integrin binding property.
  • the cyclic peptide having a specific structure according to the present disclosure has both an excellent molecule stability and an excellent integrin binding property.
  • the cyclic peptide having a specific structure according to the present disclosure contains a cyclic segment containing an RGD sequence and having 8 to 14 amino acid residues, in which a thioether bond is formed between an amino acid residue X a located on a most N-terminal side of the cyclic segment and an amino acid residue X b located on a most C-terminal side of the cyclic segment.
  • the cyclic peptide having a specific structure according to the present disclosure has an excellent molecule stability and an excellent integrin binding property.
  • an amino acid is represented by, in principle, using the name, the abbreviation, and the like adopted by INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY and INTERNATIONAL UNION OF BIOCHEMISTRY AND MOLECULAR BIOLOGY IUPAC-IUB Joint Commission on Chemical Nomenclature (JCBN).
  • an amino acid residue is represented by using an abbreviation of an amino acid from which the amino acid residue is derived.
  • an amino acid sequence (also referred to as a “primary structure”) of a peptide or protein is represented so that amino acid residues are aligned in a row from the N-terminal to the C-terminal from the left end to the right end.
  • an amino acid residue in the amino acid sequence of a peptide or protein, including the position thereof, is specified, it may be represented by adding a number indicating the number of the amino acid residue from the N-terminal side to the right side of the abbreviation of the amino acid residue.
  • the lysine at the second position from the N-terminal may be represented as Lys2.
  • amino acid in a case where an amino acid is represented using the name thereof, and isomers having an enantiomeric relationship, that is, an L-form and a D-form are present, the amino acid may be, in principle, the L-form or the D-form except for the case where the distinction between the L-form and the D-form is explicitly shown.
  • isoleucine represents “L-isoleucine” or “D-isoleucine”, and the same applies to the amino acid residue.
  • the amino acid may be, in principle, the L-form or the D-form except for the case where the distinction between the L-form and the D-form is explicitly shown.
  • “Lys” represents both “L-lysine” and “D-lysine”, and the same applies to the amino acid residue.
  • the L-form and the D-form can be each independently selected for each amino acid and each amino acid residue.
  • all amino acid residues have an L-form.
  • all the amino acid residues present in the cyclic peptide may be amino acid residues having an L-form or may be amino acid residues having a D-form, or both amino acid residues having an L-form and amino acid residues having a D-form may be present.
  • an amino acid is represented by a name thereof, and an isomer having a diastereomeric relationship is present, the isomer is not included in the amino acid specified by the name.
  • the prefix “allo” is used to treat a diastereomer as a different kind of amino acid. For example, “threonine” does not include “allothreonine”. The same applies to the amino acid residue.
  • Table 1 shows names and abbreviations (one letter abbreviations and three letter abbreviations) of amino acids for which one letter abbreviations and three letter abbreviations are officially approved.
  • Amino acids that are capable of being used in the cyclic peptide according to the present disclosure are not limited to the amino acids listed in Table 1, and unusual amino acids can also be used. Examples of the unusual amino acids are listed in Table 2 below; however, the unusual amino acids are not limited thereto.
  • Any amino acid residue contained in the cyclic peptide according to the present disclosure may be chemically modified.
  • Examples of the chemical modification of an amino acid residue include N-acetylation, N-formylation, N-acylation, PEGylation, or the like of an amino group present in the amino acid residue and amidation, PEGylation, or the like of a carboxyl group present in the amino acid residue.
  • the cyclic peptide according to the present disclosure contains a cyclic segment containing an RGD sequence and having 8 to 14 amino acid residues, in which a ring is formed by the crosslinking between an amino acid residue X a located on a most N-terminal side of the cyclic segment and an amino acid residue X b located on a most C-terminal side of the cyclic segment.
  • the cyclic peptide according to the present disclosure may consist of only a cyclic segment or may have an additional amino acid residue on at least one of the N-terminal side or the C-terminal side of the cyclic segment.
  • the number of the cyclic segments is not limited to 1, and a plurality of the cyclic segments, that is, two or more thereof may be present. In a case where a plurality of cyclic segments are present, the number of cyclic segments in the cyclic peptide according to the present disclosure may be 2 to 4, may be 2 or 3, or may be 2.
  • the amino acid sequences of the plurality of cyclic segments may be the same or different from each other. Further, a cyclic segment and an adjacent cyclic segment may be directly connected, or an amino acid sequence serving as a connecting moiety may be present between the cyclic segment and the adjacent cyclic segment.
  • the amino acid sequence as the connecting moiety is not particularly limited; however, the length of each connecting moiety may be 1 to 20 amino acid residues, a may be 2 to 10 amino acid residues, and may be 3 to 5 amino acid residues.
  • the above cyclic segment contains an RGD sequence.
  • the term “cyclic segment” is used for the cyclic segment in which the above RGD sequence is contained and the number of amino acid residues is 8 to 14; however, it does not matter whether a cyclic moiety which does not correspond to the cyclic moiety having an RGD sequence and having 8 to 14 amino acid residues, for example, a cyclic moiety that does not contain an RGD sequence or a cyclic moiety in which the number of amino acid residues is outside a range of 8 to 14, is additionally present.
  • the above cyclic peptide is composed so that the above cyclic segment contains the RGD sequence.
  • the cyclic segment is composed so that the number of amino acid residue is 8 to 14.
  • the number of RGD sequences present in one cyclic segment may be one, or two, three, or four RGD sequences may be present therein.
  • the position of the RGD sequence in the cyclic segment is preferably a position to which none of the amino acid residue X a and the amino acid residue X b is adjacent.
  • the RGD sequence corresponds to the 3rd to 5th amino acid residues or corresponds the 4th to 6th amino acid residues from the viewpoint of increasing the binding property to integrin.
  • the number of amino acid residues in the cyclic segment is 8 to 14 as described above.
  • the number of amino acid residues in the cyclic segment may be 9 to 13 or may be 10 to 12. In a case where the number of amino acid residues in the cyclic segment is within this range, the intramolecular strain of the cyclic peptide does not become too large and the higher-order structure such as a helix is stabilized, and thus the cyclic peptide according to the present disclosure has an excellent integrin binding property.
  • Amino acid residues other than the RGD sequence, the amino acid residue represented by X a , and the amino acid residue represented by X b in the cyclic segment are not particularly limited as long as the binding property to integrin is not impaired.
  • Each of the amino acid residues other than the RGD sequence, the amino acid residue represented by X a , and the amino acid residue represented by X b in the cyclic segment may be an amino acid residue selected from an isoleucine residue, a valine residue, an aspartic acid residue, a glutamic acid residue, a tyrosine residue, a leucine residue, a threonine residue, a homotyrosine residue, a proline residue, a serine residue, an asparagine residue, an alanine residue, a homoserine residue, a phenylalanine residue, an arginine residue, and a glycine residue.
  • the number of the amino acid residues other than the RGD sequence, the amino acid residue represented by X a , and the amino acid residue represented by X b in the cyclic segment is 3 to 9, may be 4 to 8, or may be 5 to 7 in a case where one RGD sequence is contained in the cyclic segment.
  • the cyclic segment may be a cyclic segment represented by
  • X a represents an amino acid residue X a located on the most N-terminal side of the cyclic segment
  • X b represents an amino acid residue X b located on the most C-terminal side of the cyclic segment
  • X t represents any amino acid residue
  • the plurality of X t 's may be the same or different from each other
  • X 11 , X 21 , X 31 , X 41 , and X 51 each independently represent any one of amino acid residues
  • v5 and v7 each independently represent an integer of 0 to 6
  • v6 represents 0 or 1.
  • X 11 represents I, V, D, E, Y, L, T, or homotyrosine.
  • X 21 represents P, T, or S.
  • X 31 represents N, S, T, V, A or homoserine.
  • X 41 represents F, Y, or P.
  • (e) v6 is 1, and X 51 represents R, D, E, A, T, S, or G.
  • v5 and v7 may be each independently 0 to 4, 0 to 2, 0 or 1, or 0.
  • X t 's may be each independently an amino acid residue selected from the group consisting of A, F, G, I, L, M, P, V, and W, may be an amino acid residue selected from the group consisting of A, G, I, L, P, and V, and may be A.
  • the cyclic segment may be a cyclic segment represented by
  • X a represents an amino acid residue X a located on the most N-terminal side of the cyclic segment
  • X b represents an amino acid residue X b located on the most C-terminal side of the cyclic segment
  • X t represents any amino acid residue
  • the plurality of X t 's may be the same or different from each other
  • X 1 represents I, V, D, E, Y, L, T, or homotyrosine
  • X 2 represents P, T, or S
  • X 3 represents N, S, T, V, A or homoserine
  • X 4 represents F, Y, or P
  • X 5 represents R, D, E, A, T, S, or G,
  • v5 and v7 each independently represent an integer of 0 to 6
  • v6 represents 0 or 1.
  • v5 and v7 may be each independently 0 to 4, 0 to 2, 0 or 1, or 0.
  • X t 's may be each independently an amino acid residue selected from the group consisting of A, F, G, I, L, M, P, V, and W, may be an amino acid residue selected from the group consisting of A, G, I, L, P, and V, and may be A.
  • An amino acid residue represented by X 1 may be I, V, or T.
  • An amino acid residue represented by X 2 may be P.
  • An amino acid residue represented by X 3 may be S or T.
  • An amino acid residue represented by X 4 may be F.
  • the amino acid residue represented by X 5 may be A.
  • at least one of the above may be satisfied; however, two or more of the above may be combined, and all of the above may be combined.
  • the amino acid sequence of a region which resides between the amino acid residue X a and the amino acid residue X b may be the same sequence as the amino acid sequence of IPRGDNFR (SEQ ID NO: 1) or may be an amino acid residue in which an amino acid residue is added, deleted, or substituted with respect to the amino acid sequence of SEQ ID NO: 1.
  • the RGD region in SEQ ID NO: 1 should not be modified.
  • the total number of amino acid residues to be added is preferably 1 to 5, more preferably 1 to 3, and still more preferably 1 or 2.
  • the total number of amino acids to be added is preferably 1 to 10, more preferably 1 to 5, and still more preferably 1 to 3.
  • the total number of amino acid residues to be deleted is preferably 1 to 3, more preferably 1 or 2, and still more preferably 1.
  • the total number of amino acid residues to be substituted is preferably 1 to 5, more preferably 1 to 3, and still more preferably 1 or 2.
  • the amino acid sequence of a region which resides between the amino acid residue X a and the amino acid residue X b may include two or more of the addition, the deletion, and the substitution of amino acid residues as compared with the amino acid sequence of SEQ ID NO: 1.
  • the total number of amino acid residues to be added, deleted, or substituted is preferably 1 to 15, more preferably 1 to 10, still more preferably 1 to 5, and even still more preferably 1 to 3.
  • deletion of amino acid residues occurs at the C-terminal R residue in the amino acid sequence of SEQ ID NO: 1.
  • the amino acid sequence of a region which resides between the amino acid residue X a and the amino acid residue X b preferably has a sequence identity of 70% or more with respect to the amino acid sequence of IPRGDNFR (SEQ ID NO: 1).
  • the amino acid sequence of a region which resides between the amino acid residue X a and the amino acid residue X b preferably has 70% or more of a sequence identity, more preferably has a sequence identity of 80% or more, and still more preferably has a sequence identity of 85% or more, with respect to the amino acid sequence of IPRGDNFR (SEQ ID NO: 1).
  • the range of the amino acid sequence having a sequence identity of 70% or more with respect to the amino acid sequence of IPRGDNFR (SEQ ID NO: 1) includes the amino acid sequence of IPRGDNFR (SEQ ID NO: 1) itself.
  • sequence identity between two amino acid sequences is determined as follows.
  • the alignment of the two sequences can be carried out using, for example, an alignment algorithm and/or a program, such as FASTA or BLAST that can be used by default settings.
  • sequence identity is calculated by the following expression.
  • sequence identity [%] (the number of matching positions/the total number of positions) ⁇ 100 [%]
  • the total number of positions is the length of the alignment, and the number of matching positions is the number of positions where the kinds of amino acids match.
  • the number of amino acid residues to be added, deleted, or substituted with respect to the amino acid sequence of SEQ ID NO: 1 and the sequence identity to the amino acid sequence of SEQ ID NO: 1 have been described.
  • the regulation of the number of amino acid residues to be added, deleted, or substituted with respect to the above amino acid sequence and the regulation of the sequence identity can be applied in the same manner to the case where the sequence of the region which resides between two crosslinked amino acid residues (that is, the amino acid residues X a and X b ) in the cyclic segment in the amino acid sequences of SEQ ID NOs: 2 to 166 (that is, the amino acid sequences of the cyclic peptides 1 to 165) is set as the reference sequence.
  • the regulation of the number of amino acid residues to be added, deleted, or substituted with respect to the above amino acid sequence and the regulation of the sequence identity can be applied in the same manner to the amino acid sequence of IPRGDNF (SEQ ID NO: 169), which is a region between the homocysteine residue and the 2-amino-4-acetylamino-butanoic acid residue in the cyclic peptide 10.
  • the amino acid sequence of a region which resides between the amino acid residue X a and the amino acid residue X b may be the same sequence as any one of the amino acid sequences of IPRGDSFA (SEQ ID NO: 170), VPRGDTFA (SEQ ID NO: 171), and TPRGDTFA (SEQ ID NO: 172), or may be an amino acid residue in which an amino acid residue is added, deleted, or substituted with respect to any one of the amino acid sequences of SEQ ID NOs: 170 to 172.
  • the RGD region in SEQ ID NOs: 170 to 172 should not be modified.
  • the total number of amino acid residues to be added is preferably 1 to 5, more preferably 1 to 3, and still more preferably 1 or 2.
  • the total number of amino acids to be added is preferably 1 to 10, more preferably 1 to 5, and still more preferably 1 to 3.
  • the total number of amino acid residues to be deleted is preferably 1 to 3, more preferably 1 or 2, and still more preferably 1.
  • the total number of amino acid residues to be substituted is preferably 1 to 5, more preferably 1 to 3, and still more preferably 1 or 2.
  • the amino acid sequence of a region which resides between the amino acid residue X a and the amino acid residue X b may include two or more of the addition, the deletion, and the substitution of amino acid residues as compared with any one of the amino acid sequences of SEQ ID NOs: 170 to 172.
  • the total number of amino acid residues to be added, deleted, or substituted is preferably 1 to 15, more preferably 1 to 10, still more preferably 1 to 5, and even still more preferably 1 to 3.
  • deletion of amino acid residues occurs at the C-terminal residue in any one of the amino acid sequences of SEQ ID NOs: 170 to 172.
  • the amino acid sequence of a region which resides between the amino acid residue X a and the amino acid residue X b has a sequence identity of 70% or more with respect to any one of the amino acid sequences of IPRGDSFA (SEQ ID NO: 170), VPRGDTFA (SEQ ID NO: 171), or TPRGDTFA (SEQ ID NO: 172).
  • the amino acid sequence of a region which resides between the amino acid residue X a and the amino acid residue X b preferably has 70% or more of a sequence identity, more preferably has a sequence identity of 80% or more, and still more preferably has a sequence identity of 85% or more, with respect to any one of the amino acid sequences of SEQ ID NOs: 170 to 172.
  • the range of the amino acid sequence having a sequence identity of 70% or more with respect to any one of the amino acid sequences of SEQ ID NOs: 170 to 172 includes any one of the amino acid sequences of SEQ ID NOs: 170 to 172 itself
  • the total length (the total number of amino acid residues) of the cyclic peptide according to the present disclosure, which contains a cyclic segment may be 8 to 50 amino acid residues, may be 9 to 30 amino acid residues, may be 10 to 20 amino acid residues, and may be 11 to 15 amino acid residues. Peptide synthesis is easier in a case where the total length is shorter.
  • a region between the N-terminal of the cyclic peptide according to the present disclosure and the N-terminal of the cyclic segment may be referred to as a cyclic peptide N-terminal region or a first segment.
  • a region between the C-terminal of the cyclic peptide according to the present disclosure and the C-terminal of the cyclic segment may be referred to as a cyclic peptide C-terminal region or a second segment.
  • N-terminal region of the cyclic peptide is optional and the N-terminal region thereof may not be present.
  • the N-terminal of the cyclic segment corresponds to the N-terminal of the cyclic peptide.
  • the presence of the C-terminal region of the cyclic peptide is optional and the C-terminal region thereof may not be present.
  • the C-terminal of the cyclic segment corresponds to the C-terminal of the cyclic peptide.
  • N-terminal amino group of the cyclic peptide may be subjected to N-terminal modification such as N-acetylation, N-formylation, N-acylation, or PEGylation.
  • C-terminal carboxy group of the cyclic peptide may be subjected to C-terminal modification such as amidation or PEGylation.
  • the cyclic peptide according to the present disclosure may be a cyclic peptide represented by Formula II.
  • X a represents an amino acid residue located on the most N-terminal side of the cyclic segment
  • X b represents an amino acid residue located on the most C-terminal side of the cyclic segment, where a thioether bond is formed between the amino acid residue X a and the amino acid residue X b ,
  • X represents any amino acid residue, where in a case where a plurality of X's are present, the plurality of X's may be the same or different from each other,
  • R N represents an N-terminal group
  • R C represents a C-terminal group
  • X 6 and X 7 each independently represent an amino acid residue having an immobilizing functional group in a side chain, where in a case where a plurality of X 6 's or X 7 's are present, the plurality of X 6 's or X 7 's may be the same or different from each other,
  • n and n are integers and simultaneously satisfy 0 ⁇ m ⁇ 9, 0 ⁇ n ⁇ 9, and 3 ⁇ m+n ⁇ 9,
  • p0 and q0 are integers and respectively satisfy 0 ⁇ p0 ⁇ 15 and 0 ⁇ q0 ⁇ 15,
  • t0 and u0 are integers and respectively satisfy 0 ⁇ t0 ⁇ 5 and 0 ⁇ u0 ⁇ 5,
  • v0 and w0 are integers and respectively satisfy 0 ⁇ v0 ⁇ 5 and 0 ⁇ w0 ⁇ 5, and
  • p0, q0, t0 , u0, v0, and w0 satisfy 0 ⁇ p0+q0+t0+u0+v0+w0 ⁇ 39.
  • a subscript is an integer indicating how many amino acid residues represented by the symbol described just before the subscript are present.
  • p0 in the notation of X p0 indicates that p0 pieces of amino acid residues represented by X are alignedly present.
  • the subscript represents an integer of 2 or more
  • a plurality of amino acid residues represented by the symbol described just before the subscript are present; however, the plurality of amino acid residues may be the same or different from each other as long as the definition thereof is satisfied.
  • X a -X m -R-G-D-X n -X b corresponds to the cyclic segment. Preferred examples of X a and X b will be described later.
  • X 6 and X 7 each independently represent an amino acid residue having an immobilizing functional group in the side chain.
  • the plurality of X 6 's or X 7 's may be the same or different from each other.
  • immobilizing functional group refers to a functional group capable of forming a covalent bond by reacting with a functional group on a base material or a holding material, which will be described later.
  • Examples of the immobilizing functional group include an amino group, a carboxy group, a hydroxy group, a thiol group, an aldehyde group (a formyl group), a carbamoyl group, an azide group, and an alkynyl group.
  • Examples of the combination of the immobilizing functional group contained in the cyclic peptide according to the present disclosure and the functional group on the base material or the holding material include a combination of an amino group and a carboxy group, a combination of an amino group and an aldehyde group, a combination of an amino group and an epoxy group, a combination of a hydroxy group and an epoxy group, a combination of a carboxy group and a hydroxy group, a combination of a thiol group and an epoxy group, and a combination of an azide group and an alkynyl group.
  • the immobilizing functional group contained in the cyclic peptide according to the present disclosure reacts with a functional group on the base material or the holding material to form a covalent bond, whereby the cyclic peptide according to the present disclosure is immobilized on the base material or the holding material.
  • the immobilizing functional group is preferably at least one selected from the group consisting of an amino group, a thiol group, and an aldehyde group, and more preferably at least one selected from the group consisting of an amino group and a thiol group.
  • the amino acid having an immobilizing functional group in the side chain is preferably at least one amino acid selected from the group consisting of an L-lysine, a D-lysine, an L-cysteine, a D-cysteine, an L-homocysteine, and a D-homocysteine.
  • the amino group can be bonded to the carboxy group on the base material or the holding material through an amide bond, and thus the cyclic peptide according to the present disclosure can be easily immobilized on the base material or the holding material.
  • the thiol group in a case where a thiol group is used as the immobilizing functional group, the thiol group can be bonded to the epoxy group on the base material or the holding material through a covalent bond, and thus the cyclic peptide according to the present disclosure can be easily immobilized on the base material or the holding material.
  • amino acid residue having an amino group in the side chain examples include an L-lysine residue and a D-lysine residue
  • examples of the amino acid residue having a thiol group in the side chain include an L-cysteine residue and a D-cysteine residue. Since these amino acid residues can be introduced at a relatively low cost, the production cost of the cyclic peptide according to the present disclosure can be reduced. For this reason, the use of the above amino acid residues is preferable from an economical viewpoint.
  • t0 and u0 are integers that respectively satisfy 0 ⁇ t0 ⁇ 5 and 0 ⁇ u0 ⁇ 5.
  • t0 preferably satisfies 0 ⁇ t0 ⁇ 3 and more preferably satisfies 0 ⁇ t0 ⁇ 2.
  • u0 preferably satisfies 0 ⁇ u0 ⁇ 3, and more preferably satisfies 0 ⁇ u0 ⁇ 2.
  • X in X p0 , X q0 , X v0 , and X w0 represents any amino acid residue, and in a case where a plurality of X's are present, the plurality of X's may be the same or different from each other.
  • X may be an amino acid residue and is not particularly limited; however, it is preferably an amino acid residue derived from an amino acid selected from the group consisting of the amino acids (excluding B, Z, and X) listed in Table 1 and the amino acids listed in Table 2, and it is more preferably an amino acid residue derived from an amino acid selected from the group consisting of the amino acids (excluding B, Z, and X) listed in Table 1.
  • an amino acid residue derived from an enantiomer or a diastereomer of the above amino acid in a case of being present, may also be used.
  • p0 described above and q0 described above are integers and respectively satisfy 0 ⁇ p0 ⁇ 15 and 0 ⁇ q0 ⁇ 15.
  • p0 preferably satisfies 0 ⁇ p0 ⁇ 10, more preferably satisfies 0 ⁇ p0 ⁇ 5, still more preferably satisfies 0 ⁇ p0 ⁇ 3, and even still more preferably satisfies 0 ⁇ p0 ⁇ 2.
  • q0 preferably satisfies 0 ⁇ q0 ⁇ 10, more preferably satisfies 0 ⁇ q0 ⁇ 5, still more preferably satisfies 0 ⁇ q0 ⁇ 3, and even still more preferably 0 ⁇ q0 ⁇ 2.
  • v0 described above and w0 described above are integers that respectively satisfy 0 ⁇ v0 ⁇ 5 and 0 ⁇ w0 ⁇ 5.
  • v0 preferably satisfies 0 ⁇ v0 ⁇ 3 and more preferably satisfies 0 ⁇ v0 ⁇ 2.
  • w0 preferably satisfies 0 ⁇ w0 ⁇ 3 and more preferably satisfies 0 ⁇ w0 ⁇ 2.
  • Each X in X m and X n may be any amino acid residue and, for example, may be an isoleucine residue, a valine residue, an aspartic acid residue, a glutamic acid residue, a tyrosine residue, a leucine residue, a threonine residue, a homotyrosine residue, a proline residue, a serine residue, an asparagine residue, an alanine residue, a homoserine residue, a phenylalanine residue, an arginine residue, or a glycine residue.
  • n described above and n described above are integers and simultaneously satisfy 0 ⁇ m ⁇ 9, 0 ⁇ n ⁇ 9, and 3 ⁇ m+n ⁇ 9.
  • m preferably satisfies 0 ⁇ m ⁇ 5, more preferably satisfies 0 ⁇ m ⁇ 3, and still more preferably satisfies 0 ⁇ m ⁇ 2.
  • n preferably satisfies 1 ⁇ n ⁇ 5 and more preferably satisfies 2 ⁇ n ⁇ 4.
  • n may be an integer that satisfies 2 ⁇ n ⁇ 3.
  • R N represents the N-terminal group.
  • N-terminal group examples include an amino group, and the amino group as the N-terminal group may be subjected to N-terminal modification such as N-acetylation, N-formylation, N-acylation, or PEGylation.
  • R C represents the C-terminal group.
  • Examples of the C-terminal group include a carboxy group, and the carboxy group as the C-terminal group may be subjected to C-terminal modification such as amidation or PEGylation.
  • R N is described on the left side of X v0 .
  • R N corresponds to an amino group or modified amino group of the amino acid residue represented by X a .
  • R C is described on the right side of X w0 .
  • R c corresponds to a carboxy group or modified carboxy group of the amino acid residue represented by X b .
  • the moiety of X a -X m -R-G-D-X m -X b in Formula II may be a moiety represented by Formula III (X a -X t v5 -X 11 -X 21 -R-G-D-X 31 -X 41 -X 51 v6 -X t v7 -X b ) or Formula IV (X a -X t v5 -X 1 -X 2 -R-G-D-X 3 -X 4 -X 5 v6 -X t v7 -X b ). Since the cyclic segment is a moiety represented by Formula III or Formula IV, the integrin binding property can be obtained with higher reliability.
  • the cyclic peptide may be a cyclic peptide having a structure represented by X J1 g1 -(cyclic segment)-X J2 g2 .
  • X J1 's each independently represent any amino acid residue
  • X J2 's also each independently represent any amino acid residue
  • g1 represents an integer of 0 to 8
  • g2 represents an integer of 0 to 8.
  • X J1 's each independently represents K, A, G, D, E, or ⁇ -alanine.
  • X J2 's each independently represents K, A, G, D, E, or ⁇ -alanine.
  • At least one of X J1 or X J2 may contain (K) g3 (g3 pieces of consecutive K residues), where g3 represents an integer of 2 to 6 and preferably represents 3 or 4.
  • g1 and g2 each independently represents preferably an integer of 0 to 6, may represent an integer of 0 to 4, may represent an integer of 0 to 2, may represent 0 or 1, and may represent 0.
  • X J1 g1 may be, for example, KKKA
  • X J2 g2 may be, for example, A.
  • the cyclic peptide according to the present disclosure may be a cyclic peptide represented by Formula V in a case of containing two or more cyclic segment moieties.
  • R N , X, v0, X 6 , t0, p0, X a , m, n, X b , q0, X 7 , u0, w0, and R c are each synonymous with R N , X, v0, X 6 , t0, p0, X a , m, n, X b , q0, X 7 , u0, w0, and R c in Formula (II), and the preferred examples thereof and ranges thereof are the same as those in Formula II.
  • e0 represents an integer of 0 or more. e0 may represent an integer of 0 to 20, may represent an integer of 1 to 10, and further preferably may represent an integer of 2 to 5.
  • dO represents an integer of 1 or more. d0 may represent an integer of 1 to 3, may represent 1 or 2, and may represent 1.
  • X a , X m , X n , and X b each appear a plurality of times.
  • X a 's where X a appears a plurality of times, may be the same or different from each other
  • X b 's, where X b appears a plurality of times may be the same or different from each other
  • X m 's where X m appears a plurality of times
  • X n 's where X n appears a plurality of times, may be the same or different from each other.
  • that X m 's are the same as each other means that a row of m pieces of X and a row of m pieces X are completely the same.
  • That X m 's are different from each other means that a row of m pieces of X and a row of m pieces of X differ in at least one X. The same applies to X n .
  • the number of cyclic segments is not particularly limited; however, as the number of cyclic segments becomes large, the integrin binding property tends to be capable of being improved. As the number of cyclic segments becomes small, the total number of amino acid residues can be reduced, whereby the antigenicity tends to be capable of being suppressed. From the viewpoint of the cost of synthesizing the cyclic peptide, it is preferable that the number of amino acid residues is small, and it is preferable that the number of cyclic segments is small.
  • the amino acid residue X a and the amino acid residue X b are amino acid residues that form a thioether bond between X a and X b .
  • the thioether bond is a divalent linking structure represented by R 1 -S-R 2 , where R 1 and R 2 are an organic group and both are generally a carbon atom.
  • R 1 and R 2 are an organic group and both are generally a carbon atom.
  • the technique for forming the thioether bond is not particularly limited, however; for example, in a case where a thiol group is allowed to react with an organic group having a halogen, it is possible to form a thioether bond in which a sulfur atom of the thiol group is bonded to an organic group, with the generation of a hydrogen halide.
  • the organic group having a halogen include a haloacetyl group.
  • the halogen atom of the haloacetyl group may be any one of a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, and the like. Among these, a bromine atom or a chlorine atom is preferable, and a chlorine atom is more preferable, from the viewpoint of the reactivity, the ease of formation of a thioether bond, and safety.
  • the amino acid residue X a is an amino acid residue derived from an a amino acid
  • the thioether bond is present on the side chain of an amino acid residue derived from the a amino acid but not on an amino group or modified amino group bonded to the ⁇ carbon of the a amino acid.
  • the amino acid residue X b is an amino acid residue derived from an ⁇ amino acid
  • the thioether bond is present on the side chain of an amino acid residue derived from the a amino acid but not on a carboxy group or modified carboxy group bonded to the ⁇ carbon of the a amino acid.
  • one of the amino acid residue X a and the amino acid residue X b before the formation of a thioether bond is an amino acid residue having a thiol group on the side chain, and the other thereof is an amino acid residue having an organic group having a halogen, on the side chain.
  • the amino acid residue having a thiol group on the side chain include an amino acid residue represented by the following Structural Formula (t-2) or (u-2).
  • * is a bonding site to an adjacent amino acid residue
  • x2 is an integer of 0 or more
  • x2 pieces of carbon atoms and a carbon atom at the ⁇ -position may be substituted with one or more substituents selected from the group consisting of —NH 2 , —SH, —COOH, a C 1 -C 10 alkyl group, and a C 6 -C 14 aryl group.
  • x2 may be an integer of 0 to 10, may be an integer of 0 to 6, and may be an integer of 1 to 4.
  • Examples of the C 1 to C 10 alkyl group include a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, an i-butyl group, and a tert-butyl group.
  • Examples of the C 6 to C 14 aryl group include a phenyl group, a naphthyl group, an anthranyl group, and a phenanthrene group.
  • amino acid residue having a thiol group on the side chain examples include a cysteine residue, a penicillamine residue, a homocysteine residue (a residue derived from 2-amino-4-mercaptobutanoic acid), and a residue derived from 2-amino-5-mercaptopentanoic acid.
  • amino acid residue having an organic group having a halogen, on the side chain examples include an amino acid residue represented by the following Structural Formula (p-2) or (q-2).
  • * is a bonding site to an adjacent amino acid residue
  • the halogen is any halogen atom, for example, F, Cl, Br, or I
  • x1 is an integer of 0 or more
  • x1 pieces of carbon atoms and a carbon atom at a ⁇ -position may be substituted with one or more substituents selected from the group consisting of —NH 2 , —SH, —COOH, a C 1 -C 10 alkyl group, and a C 6 -C 14 aryl group, and
  • the halogen-L is halogen atom-(CH 2 ) y1 —C( ⁇ O)— or halogen atom-(CH 2 ) y1 —C( ⁇ O)—NH—, where y1represents an integer of 0 or more and 10 or less.
  • x1 may be an integer of 0 to 10, may be an integer of 1 to 6, and may be an integer of 2 to 4.
  • y1 may be an integer of 0 to 10, may be an integer of 1 to 6, and may be an integer of 1 to 3.
  • Examples of the C 1 to C 10 alkyl group include a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, an i-butyl group, and a tert-butyl group.
  • Examples of the C 6 to C 14 aryl group include a phenyl group, a naphthyl group, an anthranyl group, and a phenanthrene group.
  • amino acid residue having an organic group having a halogen atom, on the side chain include, which are not limited thereto, amino acid residues derived from 2-amino-3-[(2-haloacetyl)amino]propanoic acid, 2-amino-4-[(2)-haloacetyl)amino]butanoic acid, N-6-haloacetylornithine, N- ⁇ -haloacetyllysine, and N- ⁇ -haloacetylhomolysine.
  • the halogen atom in these amino acid residues include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom. Among them, a chlorine atom or a bromine atom is preferable, and a chlorine atom is more preferable.
  • the amino acid residue that does not supply the sulfur atom of the thioether bond, among the amino acid residue X a and the amino acid residue X b after the formation of a thioether bond is an amino acid residue represented by the following (p) or (g).
  • * is a bonding site to an adjacent amino acid residue
  • ** is a bonding site to a sulfur atom of an amino acid residue which is a counterpart in the thioether bond
  • x1 is an integer of 0 or more
  • x1 pieces of carbon atoms and a carbon atom at a ⁇ -position may be substituted with one or more substituents selected from the group consisting of —NH 2 , —SH, —COOH, a C 1 -C 10 alkyl group, and a C 6 -C 14 aryl group,
  • **-L is **—(CH 2 ) y1 —C( ⁇ O)— or **—(CH 2 ) y1 —C( ⁇ O)—NH—, where y1 represents an integer of 0 or more and 10 or less, and x1 may be an integer of 0 to 10, may be an integer of 1 to 6, and may be an integer of 2 to 4. y1 may be an integer of 0 to 10, may be an integer of 1 to 6, and may be an integer of 1 to 3.
  • Examples of the C 1 to C 10 alkyl group include a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, an i-butyl group, and a tert-butyl group.
  • Examples of the C 6 to C 14 aryl group include a phenyl group, a naphthyl group, an anthranyl group, and a phenanthrene group.
  • amino acid residue that does not supply the sulfur atom of the thioether bond include an amino acid residue in which one of hydrogen atoms of the CH 3 moiety of the acetyl group of the amino acid residue derived from 2-amino-3-[acetylamino]propanoic acid, 2-amino-4-[acetylamino]butanoic acid, N- ⁇ -acetylornithine, N- ⁇ -acetyllysine, N- ⁇ -acetylhomolysine, and the like is substituted with a bond to an amino acid residue which is a counterpart in the thioether bond.
  • the amino acid residue that supplies the sulfur atom of the thioether bond, among the amino acid residue X a and the amino acid residue X b after the formation of a thioether bond is an amino acid residue represented by the following (t) or (u).
  • * is a bonding site to an adjacent amino acid residue
  • * * * is a bonding site to a carbon atom of an amino acid residue which is a counterpart in the thioether bond
  • x2 is an integer of 0 or more
  • x2 pieces of carbon atoms and a carbon atom at a ⁇ -position may be substituted with one or more substituents selected from the group consisting of —NH 2 , —SH, —COOH, a C 1 -C 10 alkyl group, and a C 6 -C 14 aryl group.
  • x1 may be an integer of 0 to 10
  • x6 may be an integer of 0 to 6
  • x4 may be an integer of 1 to 4.
  • Examples of the C 1 to C 10 alkyl group include a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, an i-butyl group, and a tert-butyl group.
  • Examples of the C 6 to C 14 aryl group include a phenyl group, a naphthyl group, an anthranyl group, and a phenanthrene group.
  • amino acid residue that supplies the sulfur atom of the thioether bond include amino acid residue in which a hydrogen atom of the thiol group in the cysteine residue, the penicillamine residue, the homocysteine residue (the residue derived from 2-amino-4-mercaptobutanoic acid), or the residue derived from 2-amino-5-mercaptopentanoic acid is substituted with a bond to an amino acid residue which is a counterpart in the thioether bond.
  • one of the amino acid residue X a and the amino acid residue X b is an amino acid residue of (p) or (q), and the other of the amino acid residue X a and the amino acid residue X b is a residue of (t) or (u).
  • the other of the amino acid residue X a and the amino acid residue X b is not an L-cysteine residue or a D-cysteine residue.
  • the amino acid residue that does not supply the sulfur atom of the thioether bond may be present at the N-terminal of the cyclic segment, that is, may be the amino acid residue X a or may be present at the C terminal of the cyclic segment, that is, may be the amino acid residue X b .
  • the amino acid residue that supplies the sulfur atom of the thioether bond such as the amino acid residue of (t) or (u)
  • amino acid residue of the (p) or the (q) may be a residue selected from the following (a) to (h).
  • * is a bonding site to an adjacent amino acid residue
  • ** is a bonding site to a sulfur atom of an amino acid residue which is a counterpart in the thioether bond.
  • the amino acid residue of the (t) or the (u) may be selected from the group consisting of an L-homocysteine residue, a D-homocysteine residue, an L-penicillamine residue, a D-penicillamine residue, an L-cysteine residue, and a D-cysteine residue.
  • a combination of the amino acid residue of the (a) or the (b) and the L-cysteine residue or the D-cysteine residue is excluded from the possible combinations of the amino acid residue X a and the amino acid residue X b .
  • * is a bonding site to an adjacent amino acid residue.
  • the amino acid residue of (a) is bonded to the L-cysteine residue
  • the ⁇ carbon and the sulfur atom of the cysteine residue are separated by four atoms, that is, by one nitrogen atom and three carbon atoms.
  • the number of atoms separating the ⁇ carbon of the amino acid residue which is a counterpart in the thioether bond from the sulfur atom of the cysteine residue means the number of atoms on a chain connecting the a atom and the sulfur atom, and atoms that do not participate in the chain, such as hydrogen atoms bonded to the atom on the chain are not counted.
  • the amino acid residue that supplies the sulfur atom of the thioether bond may be an amino acid residue in which the number (the total number of carbon atoms, including a branch moiety in a case where the branch is present) of carbon atoms on the side chain having the sulfur atom is 1 to 10.
  • the amino acid residue that supplies the sulfur atom of the thioether bond is preferably an amino acid residue in which the number (the total number of carbon atoms, including a branch moiety in a case where the branch is present) of carbon atoms on the side chain having the sulfur atom is 2 to 10, from the viewpoint of obtaining a higher molecule stability.
  • the number of carbon atoms on the side chain may be 2 to 6 or may be 2 or 3.
  • the amino acid residue that supplies the sulfur atom of the thioether bond may be, for example, penicillamine (the number of carbon atoms on the side chain is 3), homocysteine (the number of carbon atoms on the side chain is 2), or the like.
  • the cysteine residue has one carbon atom on the side chain.
  • the counting of carbon atoms on the side chain for penicillamine is described below.
  • * represents a bonding site to an adjacent amino acid residue.
  • the amino acid residue that supplies the sulfur atom of the thioether bond may be an amino acid residue in which the main chain and the sulfur atom on the side chain are separated by 1 to 10 carbon atoms.
  • the amino acid residue that supplies the sulfur atom of the thioether bond is preferably an amino acid residue in which the main chain and the sulfur atom on the side chain are separated by 2 to 10 carbon atoms from the viewpoint of obtaining more stable integrin binding property.
  • the a carbon and the sulfur atom are separated by 2 to 10 carbon atoms.
  • the main chain and the sulfur atom on the side chain may be separated by 2 to 6 carbon atoms or may be separated by 2 to 4 carbon atoms.
  • amino acid residue in which the main chain and the sulfur atom on the side chain are separated by X pieces of atoms
  • the amino acid residue is an amino acid residue in which a chain consisting of X pieces of carbon atoms connects between a carbon atom on the main chain of the cyclic peptide, where the carbon atom is the starting point of the side chain, and the sulfur atom on the side chain, and the number of carbon atoms in the branch moiety branched from the chain is not counted.
  • the ⁇ carbon and the sulfur atom are separated by one carbon atom.
  • the carbon atoms in the two methyl groups, which are not contained in the chain connecting the ⁇ carbon and the sulfur atom are not counted although the ⁇ carbon and the sulfur atom are connected by —C(CH 3 ) 2 — as shown in the following structural formula.
  • the ⁇ carbon and the sulfur atom are separated by one carbon atom.
  • the ⁇ carbon and the sulfur atom are separated by two carbon atoms.
  • Cysteine and penicillamine have a stronger racemization tendency than other sulfur atom-containing amino acids such as homocysteine.
  • an amino acid such as a homocysteine residue, which satisfies the above-described regulation on the number of carbon atoms, in terms of controlling the three-dimensional structure as compared with the case of using cysteine, penicillamine, or the like, and the integrin binding property per unit amount tends to be capable of being improved since the proportion of stereoisomers having a low integrin binding property or having no integrin binding property can be reduced.
  • * represents a bonding site to an adjacent amino acid residue.
  • the amino acid residue that supplies the sulfur atom of the thioether bond is not a cysteine residue
  • the ⁇ carbon of an amino acid residue that does not supply the sulfur atom of the thioether bond and the sulfur atom of an amino acid residue that supplies the sulfur atom of the thioether bond, among the amino acid residue X a and the amino acid residue X b are separated by five or more atoms.
  • the amino acid residue that supplies the sulfur atom of the thioether bond is a cysteine residue or not
  • the a carbon of the amino acid residue that does not supply the sulfur atom of the thioether bond and the sulfur atom of the amino acid residue that supplies the sulfur atom of the thioether bond may be separated by 5 to 9 atoms, and may be separated by 5 to 7 atoms.
  • a thioether bond by reacting a thiol group with an organic group having a halogen between an amino acid residue having the thiol group on the side chain and an amino acid residue having the organic group having a halogen, on the side chain, it is possible to form the thioether bond by reacting a linear peptide before cyclization in a neutral or basic buffer solution.
  • a neutral or basic buffer solution For example, an aqueous solution containing a linear peptide may be slowly added dropwise to a Tris-HCl (pH 8.5) buffer solution and allowed to stand. Since the thioether bond formation reaction is highly reactive, the reaction proceeds rapidly under room temperature conditions without any particular heating.
  • an oligomer in which a plurality of noncyclic peptides are connected by intermolecular bonding may be formed depending on the reaction conditions. For this reason, in order to obtain only the cyclic peptide, it is preferable to purify the peptide after the cyclization reaction by reverse phase high performance liquid chromatography or the like.
  • the cyclic peptide according to the present disclosure contains at least one of the N-terminal region (the first segment) of the cyclic peptide or the C-terminal region (the second segment) of the cyclic peptide, where at least one of the first segment or the second segment may have a structure containing an amino acid residue having an immobilizing functional group in the side chain.
  • the immobilizing functional group may be an amino group or a thiol group.
  • the amino acid residue having an immobilizing functional group in the side chain may be an amino acid residue selected from the group consisting of an L-lysine residue, a D-lysine residue, an L-cysteine residue, a D-cysteine residue, an L-homocysteine residue, and a D-homocysteine residue.
  • an amino acid residue having an immobilizing functional group in the side chain the description of the amino acid residue represented by X 6 or X 7 in Formula II can be referenced.
  • At least one of the N-terminal region of the cyclic peptide or the C-terminal region of the cyclic peptide may contain a lysine residue as the amino acid residue having an immobilizing functional group in the side chain. More specifically, at least one of the N-terminal region of the cyclic peptide or the C-terminal region of the cyclic peptide may contain one lysine residue, and alternatively, may consecutively contain two or more lysine residues, may consecutively contain 2 to 10 lysine residues, and may consecutively contain 2 to 5 lysine residues, as the amino acid residue having an immobilizing functional group in the side chain.
  • amino acid residue having the above-described immobilizing functional group is preferably present at at least one of the N-terminal of the first segment or the C-terminal of the second segment of the cyclic peptide according to the present disclosure.
  • amino acid residues having an immobilizing functional group may be consecutively present at at least one of the N-terminal of the first segment or the C-terminal of the second segment of the cyclic peptide according to the present disclosure, and the number of consecutive amino acid residues having an immobilizing functional group may be, for example, 2 to 10 residues or may be 2 to 5 residues.
  • lysine residues may be consecutively present at at least one of the N-terminal of the first segment or the C-terminal of the second segment of the cyclic peptide according to the present disclosure, and the number of consecutive lysine residues may be, for example, 2 to 10 residues or may be 2 to 5 residues.
  • the first segment or the second segment may be composed of only consecutive lysine residues; however, other amino acid residues may be optionally contained.
  • the other amino acid residues may not present in a region between the consecutive lysine residues and the cyclic segment, and alternatively, the region between the consecutive lysine residues and the cyclic segment may be composed of amino acid residues of 1 to 20 residues, 1 to 10 residues, 1 to 5 residues, or 1 to 3 residues, selected from an alanine residue, a ⁇ -alanine residue, a glutamic acid residue, an aspartic acid residue, and a glycine residue.
  • an additional lysine residue may reside between the amino acid residue selected from an alanine residue, a ⁇ -alanine residue, a glutamic acid residue, an aspartic acid residue, and a glycine residue, and the cyclic segment.
  • the first segment may be composed of any amino acid residues of 1 to 20 residues, 1 to 10 residues, 1 to 5 residues, or 1 to 3 residues.
  • the first segment may contain or may not contain a lysine residue.
  • a lysine residue may be composed of at least one kind of amino acid residue, having 1 to 20 residues, 1 to 10 residues, 1 to 5 residues, or 1 to 3 residues, selected from an alanine residue, a ⁇ -alanine residue, a glutamic acid residue, an aspartic acid residue, or a glycine residue.
  • the second segment may be composed of any amino acid residues of 1 to 20 residues, 1 to 10 residues, 1 to 5 residues, or 1 to 3 residues.
  • the second segment may contain or may not contain a lysine residue.
  • a lysine residue may be composed of at least one kind of amino acid residue, having 1 to 20 residues, 1 to 10 residues, 1 to 5 residues, or 1 to 3 residues, selected from an alanine residue, a ⁇ -alanine residue, a glutamic acid residue, an aspartic acid residue, or a glycine residue.
  • the dissociation constant (the dissociation constant regarding the binding to integrin) measured by the method described in “(2) Immobilization of cyclic peptide” and “(3) Evaluation of integrin binding property” in Examples is preferably 200 nM or less, more preferably 100 nM or less, and still more preferably 50 nM or less.
  • the cyclic peptide according to the present disclosure preferably has a residual rate of 30% or more, more preferably 50% or more, and still more preferably 70% or more, where the residual rate is measured by the method described in “(4) Evaluation of molecule stability” in Examples.
  • examples of the upper limit value that can be combined with the above lower limit value include 100%.
  • the integrin in the present disclosure is not particularly limited as long as it is an integrin that recognizes the RGD sequence.
  • the integrin binding property is evaluated using integrin ⁇ v ⁇ 5; however, the integrin is not limited to this, and the cyclic peptide according to the present disclosure can also bind to an integrin that recognizes an RGD sequence, such as integrin ⁇ V ⁇ 3.
  • the molecule stability of the cyclic peptide is measured by using the alkali resistance as an indicator; however, the molecule stability of the cyclic peptide is exhibited similarly for the resistance to stimuli other than alkali, such as X ray resistance, ⁇ ray resistance, ultraviolet ray resistance, heat resistance, and chemical resistance. This is because the molecule stability basically represents that a molecule is more stable in terms of free energy.
  • the cyclic peptide according to the present disclosure is used as an affinity ligand in a carrier for affinity chromatography and the carrier is used for cell purification, the integrin binding property is maintained even in a case of being repeatedly washed with alkali, and thus the cell separation cost can be reduced.
  • cyclic peptide according to the present disclosure examples are shown in Table 3 to Table 7 below.
  • all amino acid residues are amino acid residues that do not have an optical isomer, such as an L-amino acid residue and glycine.
  • Hcy represents a homocysteine residue
  • Pen represents a penicillamine residue.
  • Dab(acetyl) represents a 2-amino-4-acetylamino-butanoic acid residue
  • Dap(acetyl) represents a 2-amino-3-acetylamino-propanoic acid residue
  • Orn(acetyl) represents an N- ⁇ -acetyl-ornithine residue
  • Lys(acetyl) represents an N- ⁇ -acetyl-lysine residue.
  • One of hydrogen atoms on the methyl group in the acetyl group in the amino acid residue containing the above acetyl group is substituted with a bond to the sulfur atom in the amino acid residue, which is a bonding partner in the thioether bond, whereby intramolecular crosslinking by the thioether bond is formed.
  • the acetyl group is omitted.
  • the cyclic peptide 49 to the cyclic peptide 53 have a C-terminal having an amidated structure in which the C-terminal carboxylic acid is amide-bonded to NH 2 .
  • ⁇ A in the cyclic peptide 51 represents a ⁇ -alanine residue
  • HmY in the cyclic peptide 68 represents a homotyrosine residue
  • HmS in the cyclic peptide 73 represents a homoserine residue.
  • the amino acid residues shown in parentheses indicate amino acid residues involved in the intramolecular crosslinking by the thioether bond.
  • the cyclic peptides 1 to 137 and the cyclic peptides 144 to 165 are preferable from the viewpoint of molecule stability. Further, the cyclic peptides 1 to 127 and the cyclic peptides 144 to 165 are more preferable from the viewpoint of the balance between molecule stability and integrin binding property.
  • the cyclic peptides 1, 92, 108, and 160 are still more preferable, and the cyclic peptides 92, 108, and 160 are still more preferable.
  • the sequence variation may be applied by considering the entire cyclic peptide as a reference sequence.
  • an amino acid sequence in which an amino acid residue is added, deleted, or substituted with respect to any one of the amino acid sequences of SEQ ID NO: 2 to SEQ ID NO: 166, is capable of being used as long as the requirements of the cyclic peptide according to the present disclosure are satisfied.
  • the RGD region in the cyclic segment should not be modified.
  • the total number of amino acid residues added, deleted, or substituted is preferably 1 to 15, more preferably 1 to 10, still more preferably 1 to 5, even still more preferably 1 to 3, and even further still more preferably 1 or 2.
  • the cyclic peptide according to the present disclosure preferably has a sequence identity of 70% or more, more preferably has a sequence identity of 80% or more, and still more preferably has a sequence identity of 90%, with respect to any one of the amino acid sequences of SEQ ID NO: 2 to SEQ ID NO: 166.
  • the range of the amino acid sequence having a sequence identity of 70% or more with respect to the amino acid sequence of SEQ ID NO: 2 also includes the amino acid sequence of SEQ ID NO: 2 itself
  • the present disclosure also provides a cell scaffold material (hereinafter, also referred to as a cell scaffold material according to the present disclosure) containing a base material and the cyclic peptide according to the present disclosure.
  • a cell scaffold material hereinafter, also referred to as a cell scaffold material according to the present disclosure
  • a base material such as polylactic acid, polyglycolic acid, and polycaprolactone
  • collagen or gelatin which is a heat-denatured product of collagen
  • glycoproteins such as fibronectin
  • polysaccharides such as hyaluronic acid, chitin, and alginic acid.
  • the cyclic peptide according to the present disclosure can be bound to the base material.
  • the cyclic peptide according to the present disclosure has an amino group of a lysine residue as the immobilizing functional group, the amino group is reacted with a carboxy group on the base material to form an amide bond, whereby the cyclic peptide can be immobilized to the base material.
  • the amount of the cyclic peptide according to the present disclosure is not particularly limited; however, it may be 0.01% by mass to 100% by mass and may be 0.1% by mass to 50% by mass with respect to the base material.
  • the cell scaffold material according to the present disclosure can be applied onto any culture tool such as a petri dish, a flask, a plate (for example, a polystyrene well plate), a culture bag, a hollow fiber membrane, or beads. Since the cell scaffold material according to the present disclosure contains the cyclic peptide according to the present disclosure, it has a good binding property to integrin, and thus cells can adhere well to the cell scaffold material.
  • the cell to be cultured is not particularly limited as long as it is a cell of an organism expressing integrin; however, it may be any animal cell, may be any vertebrate animal cell, may be any mammal cell, and may be a human cell or a non-human mammal cell.
  • Examples of the cell include an embryonic stem (ES) cell, an induced pluripotent stem (iPS) cell, a perinatal stem cell, an amniotic fluid-derived stem cell (AFSC), a mesenchymal stem cell (MSC) of any origin, any tissue-type progenitor cell or adult cell of which the differentiation direction has been determined, a mature cell, a normal cell, an affected cell, and a tumor cell. More specific examples thereof include a liver cell, a parenchymal cell, a stellate cell, an endothelial cell, a hepatocyte, a bile duct cell, a biliary tree cell, and a pancreatic cell. Examples of these cells are also applied to the cell separating material and the medium described later.
  • the present disclosure also provides a cell separating material (hereinafter, also referred to as a cell separating material according to the present disclosure) containing a holding material and the cyclic peptide according to the present disclosure. Since the cell separating material according to the present disclosure contains the cyclic peptide according to the present disclosure, it can bind to the integrin on the cell surface and capture cells. As a result, in a case where the cell separating material according to the present disclosure is used, for example, in affinity chromatography, cells can be efficiently separated from the cell suspension.
  • a cell separating material hereinafter, also referred to as a cell separating material according to the present disclosure
  • the cyclic peptide according to the present disclosure in a case where an immobilizing functional group in the cyclic peptide according to the present disclosure is reacted with a functional group in the holding material, the cyclic peptide according to the present disclosure can be bound to the holding material.
  • the cyclic peptide according to the present disclosure has an amino group of a lysine residue as the immobilizing functional group, the amino group is reacted with a carboxy group on the holding material to form an amide bond, whereby the cyclic peptide can be immobilized to the holding material.
  • the holding material may be composed of a material selected from, for example, polysaccharides such as agarose, dextran, starch, cellulose, pullulan, chitin, chitosan, cellulose triacetate, and cellulose diacetate, and derivatives thereof, and vinyl-based polymers such polyacrylamide, polymethacrylamide, polyacrylate, polymethacrylate, polyalkyl vinyl ether, and polyvinyl alcohol. These materials may form a crosslinking structure. The crosslinking structure tends to improve mechanical strength.
  • the holding material is preferably composed of one or more of the above materials.
  • the holding material is preferably porous, more preferably a porous membrane or porous particles, and still more preferably porous particles.
  • a cell separating material in which the cyclic peptide according to the present disclosure is immobilized to a water-insoluble holding material can also be used in affinity chromatography.
  • the water-insoluble holding material include polysaccharides such as crystalline cellulose, crosslinked cellulose, crosslinked agarose, crosslinked dextran, and crosslinked pullulan, organic holding materials such as an acrylate-based polymer, and a styrene-based polymer, inorganic holding material such as a glass bead and silica gel, and composite holding materials obtained by combining these, such as an organic-organic type and an organic-inorganic type.
  • the water-insoluble holding material is more preferably polysaccharides or an acrylate-based polymer and still more preferably polysaccharides such as agarose and cellulose from the viewpoint of alkali resistance.
  • Examples of the commercially available product that can be used as a water-insoluble holding material include Cellufine (CELLUFINE is a registered trade name) GCL2000 (manufactured by INC Corporation) and Cellufine MAX (manufactured by INC Corporation), which are porous cellulose gels; Sephacryl (SEPHACRYL is a registered trade name) S-1000 SF (manufactured by GE Healthcare) in which allyl dextran and methylenebisacrylamide are covalently crosslinked; TOYOPEARL (TOYOPEARL is a registered trade name) (manufactured by Tosoh Corporation), TOYOPEARL AF-Carboxy-650 (manufactured by Tosoh Corporation), and TOYOPEARL GigaCap CM-650 (
  • the water-insoluble holding material in the present disclosure is not limited to these holding materials or activated holding materials.
  • the water-insoluble holding material that is used in the present disclosure preferably has a large surface area and is preferably a porous material having a large number of pores of a proper size in consideration of the using purpose and the using method of the present adsorbing material.
  • the form of the holding material is not particularly limited. Any form such as a bead shape, a fibrous shape, a membrane shape, or a hollow yarn shape, is possible, and any form can be selected.
  • Examples of the method of immobilizing the cyclic peptide according to the present disclosure to a water-insoluble holding material include, which are not limited to, an immobilization method using an amino group of a lysine residue as described above. It is possible to adopt a method generally adopted in a case of immobilizing a protein or a polypeptide to a holding material.
  • Examples thereof include a method in which a holding material is reacted with cyanogen bromide, epichlorohydrin, diglycidyl ether, tosyl chloride, tresyl chloride, hydrazine, or the like to activate the holding material or introduce a reactive functional group on the surface of the holding material and a reaction with the cyclic peptide according to the present disclosure is carried out for immobilization and an immobilization method in which a condensing reagent such as carbodiimide or a reagent having a plurality of functional groups in the molecule, such as glyceraldehyde, is added to a system in which a holding material and the cyclic peptide according to the present disclosure are present to carry out condensation and crosslinking
  • aqueous solvent an aqueous dispersion medium
  • organic solvent an organic dispersion medium
  • HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
  • the organic solvent is not particularly limited; however, a polar organic solvent is preferable, and dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF), or alcohol is particularly preferable. Examples thereof include methanol, ethanol, isopropyl alcohol (IPA), 2,2,2-trifluoroethanol (TFE), and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP).
  • DMSO dimethyl sulfoxide
  • DMF N,N-dimethylformamide
  • alcohol is particularly preferable.
  • examples thereof include methanol, ethanol, isopropyl alcohol (IPA), 2,2,2-trifluoroethanol (TFE), and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP).
  • the pH condition for immobilizing the cyclic peptide according to the present disclosure is not particularly limited, and may be any condition of acidic, neutral, or alkaline condition, and may be appropriately set according to, for example, the solvent (the dispersion medium) to be used.
  • a base such as diazabicycloundecene (DBU) or triethylamine (TEA) may be added to dimethyl sulfoxide (DMSO) or alcohol.
  • DBU diazabicycloundecene
  • TAA triethylamine
  • the density of the cyclic peptide according to the present disclosure is not particularly limited; however, it is preferably 0.1 to 1,000 mmol/1 L packing material, more preferably 0.1 to 100 mmol/1 L packing material, and still more preferably 0.5 to 20 mmol/1 L packing material. Within this range, the using amount of the cyclic peptide according to the present disclosure is well balanced with the cell separation performance, and cells can be separated efficiently at a lower cost.
  • the cell that is separated by the cell separating material according to the present disclosure is not particularly limited as long as it is a cell of an organism expressing integrin; however, it may be any animal cell, may be any vertebrate animal cell, may be any mammal cell, and may be a human cell or a non-human mammal cell.
  • the present disclosure also provides a medium (hereinafter, also referred to as a medium according to the present disclosure) containing a culture component and the cyclic peptide according to the present disclosure.
  • a medium hereinafter, also referred to as a medium according to the present disclosure
  • the binding of the integrin of the cell cultured in the medium to the cyclic peptide occurs, which provides an effect such as an increase in cell viability through apoptosis suppression due to signal transduction from the integrin.
  • the culture component refers to a medium component for culturing cells.
  • the cell to be cultured is not particularly limited as long as it is a cell of an organism expressing integrin; however, it may be any animal cell, may be any vertebrate animal cell, may be any mammal cell, and may be a human cell or a non-human mammal cell.
  • an appropriate medium may be selected according to the kind of cells to be cultured.
  • DMEM Dulbecco modified Eagle's medium
  • MEM Eagle's minimum essential medium
  • F12 Ham
  • Ham Ham
  • RPMI 1640 MCDB (MCDB 102, 104, 107, 131, 153, 199, or the like)
  • L15 SkBM (registered trade name)
  • RITC80-7 MesenPro (Thermo Fisher Scientific, Inc.).
  • the culture component a medium such as the above-described medium may be used as it is in the state of the standard composition (for example, as it is in the state of having been sold), or the composition may be appropriately changed according to the cell kind or the cell conditions. Accordingly, the culture component is not limited to the one having a known composition, and one or two or more components may be added, removed, increased, or decreased.
  • the amino acids to be contained in the culture component are not particularly limited; however, examples thereof include L-arginine, L-cystine, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine.
  • the vitamins to be contained in the culture component is not particularly limited; however, examples thereof include calcium D-pantothenate, choline chloride, folic acid, i-inositol, niacinamide, riboflavin, thiamine, pyridoxine, biotin, lipoic acid, vitamin B12, adenine, and thymidine.
  • the electrolyte to be contained in the culture component is not particularly limited; however, examples thereof include CaCl 2 , KCl, MgSO 4 , NaCl, NaH 2 PO 4 , NaHCO 3 , Fe(NO 3 ) 3 , FeSO 4 , CuSO 4 , MnSO 4 , Na 2 SiO 3 , (NH 4 ) 6 Mo 7 O 24 , NaVO 3 , NiCl 2 , and ZnSO 4 .
  • the culture component may contain sugars such as D-glucose, sodium pyruvate, a pH indicator such as phenol red, putrescine, and an antibiotic.
  • sugars such as D-glucose, sodium pyruvate, a pH indicator such as phenol red, putrescine, and an antibiotic.
  • the culture component may contain or may not contain serum.
  • the content of the serum in the medium according to the present disclosure is preferably 0% by volume or more and 30% by volume or less, more preferably 0% by volume or more and 10% by volume or less, and still more preferably 0% by volume or more and 5% by volume or less, and particularly preferably 0% by volume or more and 2% by volume or less.
  • the content of the cyclic peptide according to the present disclosure in the medium according to the present disclosure is not particularly limited; however, it is, for example, 0.01 ng/mL to 10 mg/mL and may be 0.1 ng/mL to 1 mg/mL.
  • the medium according to the present disclosure unlike the case of the cell scaffold material or the cell separating material, it is not particularly necessary to immobilize the cyclic peptide.
  • a cyclic peptide excellent in the binding property to integrin and excellent in the molecule stability for example, in the alkali resistance, and a cell scaffold material, a cell separating material, and a medium, which contain the cyclic peptide.
  • each of the cyclic peptides 1 to 146 shown in Table 3 to Table 7 and the cyclic peptides 147 and 148 shown in Table 8 below was synthesized by using a fully automated peptide synthesizer (PSSM-8, manufactured by Shimadzu Corporation).
  • PSSM-8 fully automated peptide synthesizer
  • all the amino acid residues are L-form isomers. That is, for example, the notation D in the peptide prepared in Example represents an L-aspartic acid residue.
  • the amino acid residues shown in parentheses indicate amino acid residues involved in the intramolecular crosslinking by the thioether bond.
  • a commercially available CMS (a carboxymethyl dextran introduction type, manufactured by GE Healthcare) sensor chip was set in Biacore 3000, which is a surface plasmon resonance apparatus manufactured by GE Healthcare, the sensor was stabilized at a flow rate of 10 ⁇ L/min of a HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer solution (20 mM HEPES-HCl, 150 mM NaCl, pH 7.4) for surface plasmon resonance (SPR), and 70 ⁇ L of a mixed aqueous solution of 0.2 M 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and 0.04 M N-hydroxysuccinimide (NHS) was added thereto.
  • HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
  • the concentration unit M represents mol/L, and the same applies hereinafter. Then, 20 ⁇ L of the sample solution of each of the above cyclic peptides diluted to 0.2 g/L with the HEPES buffer solution was supplied to the sensor chip, blocking treatment was subsequently carried out with an ethanolamine solution, and washing was carried out with a sodium hydroxide aqueous solution, whereby immobilization was carried out. However, only for the cyclic peptides 125, 126, and 127, in which the number of lysine residues having an amino group as the immobilizing functional group was zero, the amount of the sample solution to be supplied to the sensor chip was set to 500 ⁇ L instead of 20 ⁇ L.
  • immobilization-treated sensor chip A the obtained immobilization-treated sensor chip is referred to as an “immobilization-treated sensor chip A”.
  • the above-described measurement process consisting of adding integrin for 10 minutes, allowing a running buffer to flow for 30 minutes, carrying out measurement with Biacore 3000, and carrying out regeneration treatment with 0.5 M EDTA aqueous solution was carried out in the same manner for 100 nM human integrin ⁇ v ⁇ 5, 300 nM human integrin ⁇ v ⁇ 5, and 1,000 nM human integrin ⁇ v ⁇ 5.
  • Dissociation constant between the cyclic peptide and human integrin ⁇ v ⁇ 5 was calculated from the difference between the value measured by Biacore 3000 in the flow channel immobilized with the cyclic peptide and the value measured by Biacore 3000 in the flow channel unimmobilized with the cyclic peptide, in a case where each concentration of human integrin ⁇ v ⁇ 5 was allowed to flow, and the integrin binding property was evaluated according to the following evaluation standards. It is preferable that the evaluation result satisfies the evaluation standard A, B, or C.
  • the dissociation constant is 50 nM or less.
  • the dissociation constant is more than 50 nM and 100 nM or less.
  • the dissociation constant is more than 100 nM and 200 nM or less.
  • the dissociation constant is more than 200 nM.
  • the molecule stability of the cyclic peptide was evaluated by analyzing the alkali-treated cyclic peptide aqueous solution by liquid chromatography mass spectroscopy (LC/MS).
  • the alkali treatment was carried out by the following method.
  • a 500 ⁇ M cyclic peptide aqueous solution was prepared, an equivalent of 1 M sodium hydroxide aqueous solution was added to this aqueous solution, and the resultant mixture was incubated at 15° C. for 3 hours to obtain an alkali-treated cyclic peptide aqueous solution.
  • the cyclic peptide residual rate was calculated by setting the total area of all peaks of the cyclic peptide before alkali treatment in LC/MS to 100% and determining the proportion of the total area of all peaks in LC/MS of the alkali-treated cyclic peptide aqueous solution, and the molecule stability was evaluated according to the following evaluation standards. It is preferable that the evaluation result satisfies the evaluation standard A, B, or C.
  • the residual rate of the cyclic peptide is 70% or more.
  • the residual rate of the cyclic peptide is 50% or more and less than 70%.
  • the residual rate of the cyclic peptide is 30% or more and less than 50%.
  • the residual rate of the cyclic peptide is less than 30%.
  • the cyclic peptide in a case where the cyclic peptides exhibiting molecule stability of the ranks A to C are used, the cyclic peptide can be specifically bound to cells even in a case of being used for a long period of time or repeatedly, cell control is possible even in a case of being used in a long-term or repeated process, and thus the cost can be further reduced.
  • the cyclic peptides 1 to 165 according to the present disclosure have a practically sufficient integrin binding property and a practically sufficient molecule stability. All of the cyclic peptides 1 to 165 according to the present disclosure had a residual rate value of more than 35% in the evaluation of molecule stability.
  • the cyclic peptide 166 and the cyclic peptide 167 in which the sulfur atom of the cysteine residue and the ⁇ carbon of another amino acid residue were separated by four or fewer atoms, a practically sufficient molecule stability could be obtained.
  • both the cyclic peptide 166 and the cyclic peptide 167 had a value of a residual rate of less than 25% in the evaluation of molecule stability.
  • the cyclic peptides 1 to 137 and the cyclic peptides 144 to 165 where the amino acid residue in which the number (the total number of carbon atoms, including a branch moiety in a case where the branch is present) of carbon atoms on the side chain containing the sulfur atom is 2 to 10 is one of amino acid residues involved in the intramolecular crosslinking, have an improved molecule stability as compared with the cyclic peptides 138 to 143, where the cysteine residue in which the number of carbon atoms on the side chain having the sulfur atom is one is one of amino acid residues involved in the intramolecular crosslinking
  • the cyclic peptide where the amino acid residue in which the carbon atom of the main chain and the sulfur atom on the side chain are separated by 2 to 10 carbon atoms is one of amino acid residues involved in the intramolecular crosslinking
  • a cell scaffold material was prepared using the obtained peptide, and an iPS cell culture experiment was carried out.
  • a plasma treating device (SCB-106 manufactured by SAKIGAKE-Semiconductor Co., Ltd.), a 6-well plate (manufactured by Corning Incorporated) made of polystyrene was subjected to surface treatment in an ammonia gas under the conditions of a gas pressure of 10 Pa, an output of 700 W, and a treatment time of 5 minutes.
  • CMD carboxymethyl dextran
  • EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
  • NHS N-hydroxysuccinimide
  • 0.05 mL of the EDC solution and 0.05 mL of the NHS solution were added to 10 g of the CMD solution prepared above and stirred, and 1 mL of the obtained CMD-containing coating solution was immediately added dropwise to one of wells of the polystyrene plate subjected to surface treatment as described above. After allowing the polystyrene plate to stand at room temperature for 1 hour, the well was sufficiently washed with distilled water to remove the CMD-containing coating solution, whereby a CMD coating well was obtained.
  • a well (hereinafter referred to as a “ligand coating well”) having a cell scaffold material, on which the cyclic peptide 92 was immobilized on CMD as a base material.
  • irradiated cell scaffold material A a ⁇ ray irradiated cell scaffold material (hereinafter, referred to as an “irradiated cell scaffold material A”) was obtained.
  • a cell dissociation reagent manufactured by Thermo Fisher Scientific, Inc., product name: TrypLE Select.
  • Hcy represents a homocysteine residue
  • Dab(acetyl) represents a 2-amino-4-acetylamino-butanoic acid residue
  • Dap(acetyl) represents a 2-amino-3-acetylamino-propanoic acid residue.
  • the cell scaffold material containing the cyclic peptide according to the present disclosure is more stable against ⁇ rays and the like than the cell scaffold material containing the cyclic peptide of Comparative Example, and has good cell proliferation performance even in a case where sterilization treatment with ⁇ rays or the like is carried out.
  • JP2019-108962 filed on June 11, 2019, is incorporated in the present specification by reference in its entirety.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Immunology (AREA)
  • Sustainable Development (AREA)
  • Peptides Or Proteins (AREA)
US17/643,533 2019-06-11 2021-12-09 Cyclic peptide, cell scaffold material, cell separating material, and medium Pending US20220089647A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019108962 2019-06-11
JP2019-108962 2019-06-11
PCT/JP2020/022558 WO2020250854A1 (ja) 2019-06-11 2020-06-08 環状ペプチド、細胞足場材、細胞分離材、及び培地

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/022558 Continuation WO2020250854A1 (ja) 2019-06-11 2020-06-08 環状ペプチド、細胞足場材、細胞分離材、及び培地

Publications (1)

Publication Number Publication Date
US20220089647A1 true US20220089647A1 (en) 2022-03-24

Family

ID=73780900

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/643,533 Pending US20220089647A1 (en) 2019-06-11 2021-12-09 Cyclic peptide, cell scaffold material, cell separating material, and medium

Country Status (5)

Country Link
US (1) US20220089647A1 (de)
EP (1) EP3967704A4 (de)
JP (1) JP7220782B2 (de)
CN (1) CN113993882A (de)
WO (1) WO2020250854A1 (de)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017492A1 (en) 1991-04-05 1992-10-15 Genentech, Inc. PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIII¿a?
RU2303042C2 (ru) 2001-07-10 2007-07-20 Джи-И Хелткер АС Соединения на основе пептидов для направленной доставки к рецепторам интегринов
CA2550312A1 (en) * 2003-12-24 2005-07-21 Pfizer Products Inc. Retinal toxicity screening methods
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
WO2011156686A2 (en) * 2010-06-11 2011-12-15 The Regents Of The University Of Colorado, A Body Corporate Method for synthesizing a cyclic multivalent peptide using a thiol-mediated reaction
US10316069B2 (en) * 2015-06-26 2019-06-11 Spiber Technologies Ab Cyclic RGD cell-binding motif and uses thereof
CN110603261A (zh) * 2016-12-23 2019-12-20 拜斯科阿迪有限公司 具有新型键结构的肽衍生物
JP7009200B2 (ja) 2017-12-20 2022-01-25 三菱パワー株式会社 スプレイパイプ、それを備えた脱硫装置およびその点検方法

Also Published As

Publication number Publication date
EP3967704A4 (de) 2022-08-31
JP7220782B2 (ja) 2023-02-10
JPWO2020250854A1 (de) 2020-12-17
EP3967704A1 (de) 2022-03-16
WO2020250854A1 (ja) 2020-12-17
CN113993882A (zh) 2022-01-28

Similar Documents

Publication Publication Date Title
JP6785652B2 (ja) ベータ−ヘアピンペプチド模倣体
US11066446B2 (en) Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation
US20220098240A1 (en) Cyclic peptide, cell scaffold material, cell separating material, and medium
RU2694050C1 (ru) Циклический пептид, подложка для аффинной хроматографии, меченое антитело, конъюгат антитела и лекарственного средства и фармацевтический препарат
WO2007065691A2 (en) Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
WO2012133610A1 (ja) 細胞接着性タンパク質
EP2046814A2 (de) Minimierte kleine peptide mit hoher affinität für faktor viii und faktor-viii-ähnliche proteine
US20220089647A1 (en) Cyclic peptide, cell scaffold material, cell separating material, and medium
US11565240B2 (en) Mixed mode affinity chromatography carrier
JP2008150393A (ja) 拡張天然型化学的ライゲーション
JP2015524791A (ja) β−ターン環式ペプチド模倣化合物の合成
JP2011030453A (ja) 細胞の生産方法
JP6024101B2 (ja) 血液凝固因子又は細胞接着因子に対する吸着剤及び精製方法
JPWO2017026156A1 (ja) 多能性幹細胞の培養方法、培養容器の製造方法、培養容器、及び細胞培養用の足場材料
WO2013002311A1 (ja) 幹細胞培養用基材及びそれを用いた培養方法
WO2024195711A1 (ja) 環状ペプチド又はその塩及びそれらの利用
WO1995008566A1 (fr) Nouveau peptide
JPWO2016167143A1 (ja) 短鎖ペプチド固定化担体の製造方法および短鎖ペプチド固定化担体

Legal Events

Date Code Title Description
AS Assignment

Owner name: FUJIFILM CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MINAMI, KOICHI;REEL/FRAME:058349/0310

Effective date: 20210915

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED